MARKET

LPCN

LPCN

Lipocine Inc
NASDAQ
3.318
-0.102
-2.98%
Pre Market: 3.390 +0.072 +2.16% 08:05 05/07 EDT
OPEN
3.430
PREV CLOSE
3.420
HIGH
3.600
LOW
3.162
VOLUME
42
TURNOVER
0
52 WEEK HIGH
11.79
52 WEEK LOW
2.750
MARKET CAP
17.75M
P/E (TTM)
2212.13
1D
5D
1M
3M
1Y
5Y
1D
Lipocine Partners with Aché for TLANDO® in Brazil
TipRanks · 23h ago
Lipocine inks license and supply agreement for TLANDO in Brazil
Seeking Alpha · 1d ago
Lipocine Enters Into License And Supply Agreement With Aché Laboratórios Farmacêuitcos S.A Granting Exclusive Rights To Market Tlando in Brazil.
Benzinga · 1d ago
LIPOCINE ANNOUNCES LICENSE AND SUPPLY AGREEMENT FOR TLANDO® IN BRAZIL
Reuters · 1d ago
Weekly Report: what happened at LPCN last week (0428-0502)?
Weekly Report · 2d ago
Weekly Report: what happened at LPCN last week (0421-0425)?
Weekly Report · 04/28 09:37
Weekly Report: what happened at LPCN last week (0414-0418)?
Weekly Report · 04/21 09:38
Weekly Report: what happened at LPCN last week (0407-0411)?
Weekly Report · 04/14 09:35
More
About LPCN
More
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Recently
Symbol
Price
%Change

Webull offers Lipocine Inc stock information, including NASDAQ: LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.